The Bakersfield Californian

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for ...

Takeda ( TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the ...
Yahoo Finance

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for ...

OSAKA, Japan & CAMBRIDGE, Mass., February 10, 2026--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) ...
PharmiWeb

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for ...

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and ...
WNCT

Application window for high school scholarship open

GREENVILLE, N.C. (WNCT) — The priority application window for the North Carolina Opportunity Scholarship is officially open for families interested in a private school education for their child. The ...
MarketWatch

Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

The MarketWatch News Department was not involved in the creation of this content. -- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is ...